Press Releases

Date Title and Summary Additional Formats
Toggle Summary Quotient Limited Reports Commencement of EU Blood Grouping Field Trial
JERSEY, Channel Islands , May 17, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported that it has completed the verification and validation (V&V) phase for its initial blood grouping MosaiQ™ microarray (IH I) and has commenced its European
View HTML
Toggle Summary Quotient Limited to Report Fourth Quarter and Fiscal Full Year 2018 Financial Results and Host Conference Call
JERSEY, Channel Islands , May 15, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fourth quarter and fiscal full year ended March 31, 2018 , will be released before market open on Tuesday, May 29, 2018 .
View HTML
Toggle Summary Quotient Limited Announces FDA Approval of Seven Blood Bank Reagents, Including Two Market Firsts
JERSEY, Channel Islands , April 24, 2018 /PRNewswire/ -- Quotient Limited (" Quotient") (NASDAQ: QTNT), an established, commercial-stage diagnostics company, today announced the recent FDA approval for U.S. commercialization of seven new blood bank reagents including two market firsts.
View HTML
Toggle Summary Quotient inaugurates new campus outside Edinburgh
Edinburgh, SCOTLAND, UK, 10 April 2018 – Quotient today announced the official opening of its state-of-the-art Allan-Robb Campus within the Scottish Enterprise Biocampus just outside of Edinburgh.
View HTML
Toggle Summary Quotient Limited Reports Blood Grouping Concordance Data From MosaiQ Verification and Validation Studies and Updates on the Completion of Its Sale Leaseback Transaction
Verification & Validation (“V&V”) “head-to-head” data exceeds target concordance for blood grouping Overall concordance for antigen typing – 99.8%, demonstrating robustness of the MosaiQ platform Completion of the BioCampus sale and leaseback transaction JERSEY, Channel Islands , March 26, 2018
View HTML
Toggle Summary Quotient Limited Announces Retirement of Paul Cowan, Chairman and Chief Executive Officer; Franz Walt Named as Interim Chief Executive Officer
JERSEY, Channel Islands , March 26, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the retirement of Paul Cowan as its Chairman and Chief Executive Officer. Franz Walt , who recently retired as the President of Siemens Healthineers ,
View HTML
Toggle Summary Quotient Limited to Participate in the Cowen 38th Annual Global Health Care Conference
JERSEY, Channel Islands , March 01, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan , will present at the Cowen 38 th Annual Global Health Care Conference on Tuesday,
View HTML
Toggle Summary Quotient Limited Announces the Sale and Leaseback of its Edinburgh, Scotland Manufacturing and R&D Facility
JERSEY, Channel Islands , Feb. 20, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced it has entered into definitive agreements for the sale and leaseback of its recently completed Biocampus facility located near Edinburgh, Scotland .
View HTML
Toggle Summary Quotient Limited Announces Appointment of Franz Walt as Non-Executive Director
JERSEY, Channel Islands , Feb. 20, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Franz Walt to its board of directors effective February 19, 2018 Mr. Walt joins Quotient’s board of directors with over 29 years of
View HTML
Toggle Summary Quotient Limited Updates on Status of MosaiQ Performance and Provides Third Quarter Fiscal 2018 Financial Results
Manufacturing process change implemented with improved assay performance Verification and Validation (V&V) studies for blood grouping to resume MosaiQ SDS Microarray preparing to enter into formal V&V studies European Field Trials to commence following completion of V&V studies Conventional reagent
View HTML